In their work, they used two prostate tumor antigens—prostate-specific membrane antigen (PSMA) and prostate stem cell antigen (PSCA)—and demonstrated that CAR T-cell destroyed tumor cells expressing both PSMA and PSCA. This evidence concerns the gene FOLH1 and prostate neoplasm.